Tyler Seibert MD PhD
@TylerSbrt
#radonc and #cancer scientist @UCSanDiego. Quantitative MRI. Genetic risk. http://SeibertLab.com
🏃🏼 by 💧 Any recent 🚶🏻♀️🏃🏽♀️🚴🏼 photos from my oncology friends around the 🌍 ? @VedangMurthy @aadel_chaudhuri @cwspeers @andreasroder1 @HenningWillers @brookmans76 @_ShankarSiva @ResearchWyatt @ProfAJChalmers @shiv_smith @scserendipity1 @SimonMDLord @RenuEapen @AlisonBirtle
Morning hike with the kids
Yes to both questions for Cambridge! However, I’d be cautious about such analysis, particularly using biopsies, because even with basal cell IHC it’s often practically impossible to confidently classify something as IDC/ICC. One level up/down and here’s that single basal cell 🙄
Severe Late Toxicities (Grade 3-5) with 13 Years of Follow-up after Hypofractionated Postprostatectomy Radiotherapy - International Journal of Radiation Oncology, Biology, Physics redjournal.org/article/S0360-…
Arber Roadbike #Cycling marathon today - with a lot of rain 🌧️ But worth every effort 🚴♀️😁❤️
In this #WorldHeadandNeckCancerDay Resharing my story in the hope that people newly diagnosed know there are treatment options. @RTAnswers_org rtanswers.org/survivorship/p…
This morning’s offerings hope it’s nice weather for you all 🌞 (Excuse the huffing & puffing) #NHS1000Miles
One of our stellar @ASCO LDP mentees this year, @NiuSanford @utswcancer, has put together a phenomenal series of online lectures on @YouTube (totally free!) detailing different aspects of #radonc. There is certainly some focus on GI onc, her specialty, but I think every #hemeonc…
Patient reported outcomes definitely matter!
Currently there are 32 trials in NRG that include PROs. #NRG2025
Innovation & Insights Session from @NRGonc Trials➡️ #radonc ☢️ 🧹🧹🧹🧹 #notsurprised #innovators Congrats to all the presenters on their cutting edge work! @dave_qian @a_dalpra @Qle_stanford @StanfordRadOnc Dr. Nguyen Dr. Mayadev @UCSDRadMed @RTOGFoundation
💡 With a $1 million grant from @TheVFoundation, Moores Cancer Center and @salkinstitute are changing the course of pancreatic cancer treatment. Dr. Gregory Botta is collaborating with Salk's Diana Hargreaves to improve immunotherapy treatments, identify potential biomarkers and…
Could not think of a better person to take on this tremendous role for this @AmericanCancer journal! Congrats @DrRanaMcKay! @DrChoueiri @BradMcG04 @shilpaonc @VivekSubbiah @neerajaiims @PGrivasMDPhD
Please join us in welcoming @DrRanaMcKay as our new Section Editor for Genitourinary Disease! Dr. McKay is a medical oncologist who specializes in treating people with urogenital cancers. Her research interests include precision medicine and biomarker development. @OncoAlert
Please join us in welcoming @DrRanaMcKay as our new Section Editor for Genitourinary Disease! Dr. McKay is a medical oncologist who specializes in treating people with urogenital cancers. Her research interests include precision medicine and biomarker development. @OncoAlert
@NRGonc GU core committee leading the charge. Honored to chair the intact subcommittee and kudos to @DrPaulNguyen for continuing the legacy of @felixfengmd Amazing concepts coming down the pipeline, multiple led by @RadOncUH investigators
It is possible that other molecular events associated with outcomes are enriched in high volume tumors (regardless of BRCA status), attenuating the impact of BRCA
Another @NRGonc meeting on the books! As always #NRG2025 was a great opportunity to discuss new trials and connect with colleagues. Clinical trials matter. @DrPaulNguyen @NiuSanford @laurenhenke @DrSpratticus @EdwinPosadasMD @KarynAGoodman @alexhotca